On 20 July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Fanaptum, intended for the treatment of schizophrenia. The company that applied for authorisation is Vanda Pharmaceuticals Ltd.
The company requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 9 November 2017.
Questions and answers on the refusal of the marketing authorisation for Fanaptum (iloperidone) (PDF/93.07 KB)Adopted
First published: 21/07/2017
Last updated: 10/11/2017
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Vanda Pharmaceuticals Ltd
|Date of opinion||
|Date of refusal of marketing authorisation||